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Background: Women with substance use disorders (SUDs) are a key population for HIV 
prevention with pre-exposure prophylaxis (PrEP), though uptake is limited by awareness of 
PrEP, misestimation of personal HIV risk, and minimally integrated HIV prevention and 
addiction treatment services. Patient-centered decision aids (DA) could address these barriers 
to PrEP, but no extant DA for PrEP has been published, including for women with SUDs.
Methods: We developed a patient-centered PrEP DA for women in addiction treatment. In 
a pilot randomized preference trial, we compared the DA to enhanced standard of care 
(eSOC) providing standardized information. The primary outcome was opting to receive 
more information through the DA; we also assessed the impact of the DA on PrEP decisional 
preference and PrEP uptake over 12 months.
Results: A total of 164 enrolled participants (DA: 83; eSOC: 81) were similar in terms of 
HIV risk and demographics, which are representative of women in addiction treatment 
programs nationally, and most (92%) had opioid use disorder. Half of participants were 
PrEP eligible, though 37% underestimated their personal HIV risk. Independent correlates of 
selecting the PrEP DA relative to eSOC included higher alcohol use severity (aOR 4.13, 95% 
CI 1.05–16.28, p=0.04) and perception of high risk for HIV (aOR 2.95, 95% CI 1.19–7.35, 
p=0.02). For those selecting the DA, interest in PrEP increased significantly from 25% to 
89%. DA participants were also significantly more likely than eSOC participants to see 
a provider for PrEP during follow-up (15.7% vs 6.2%; p=0.05).
Conclusion: Half of the women selected to use the DA, and those who did significantly 
increased their engagement in the HIV prevention cascade through increased interest in and 
initiation of PrEP. Future iterations should accelerate the HIV prevention cascade for women 
with SUDs by integrating PrEP decision aids into existing addiction treatment services and 
actively linking women to PrEP.
Keywords: PrEP, women, substance use disorders, decision aids
Plain Language Summary
Why was this study done? Women with substance use disorders are at high risk for HIV and 
could benefit from pre-exposure prophylaxis (PrEP) for HIV prevention but are often 
unaware of it or unable to access it. The purpose of this study was to design and test 
a tool to help women make informed decisions about PrEP.
What did the researchers do and find? We developed a decision aid about PrEP to meet 
women’s needs and recruited 164 women with substance use disorders who were in treatment 
into a clinical trial. Women could choose to receive more information about PrEP through the 
decision aid or not choose to receive more information about PrEP (and instead receive a generic 
pamphlet that is enhanced standard of care). The decision aid successfully increased women’s 
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interest in PrEP for those who received it and was associated with an 
increased chance of initiating PrEP by 12 months.
What do these results mean? The decision aid helped to 
change women’s minds about PrEP, especially those at highest 
risk for HIV, and was associated with starting PrEP, even though 
we did not directly link them to care as part of the study.
Introduction
Each year in the US, one in five new HIV infections occur 
in women.1 Although most (87%) HIV infections among 
US women are attributable to heterosexual sex, substance 
use is often involved,1 which in turn increases sexual risk- 
taking and decreases risk perception, even at non- 
disordered levels.2–4 Women with substance use disorders 
(SUDs) are a designated high priority population for tar-
geted evidence-based HIV prevention that is central to the 
US strategy for Ending the HIV Epidemic (EHE).5–7
HIV pre-exposure prophylaxis (PrEP) scale-up is one 
of the four pillars of EHE.7 PrEP has transformed the 
prevention landscape for women because, before PrEP, 
HIV biomedical prevention interventions that were effec-
tive at preventing HIV still required a male partner’s 
cooperation. In contrast, PrEP is event-independent, user- 
controlled, and partner-independent.8 A woman-controlled 
HIV prevention strategy, like oral contraceptives for 
pregnancy prevention, is critical for women who are 
violence-exposed, dependent on partners for basic subsis-
tence, and have limited autonomy to negotiate condoms 
or select sex partners.9–11 Behavioral interventions alone8 
are insufficient to reduce women’s HIV risk because they 
do not address other conditions (such as intimate partner 
violence, SUDs, and psychiatric disorders) or relation-
ships that affect women’s risk. PrEP thereby empowers 
women12,13 and has proven effective in preventing HIV 
in some trials of heterosexual sero-discordant couples 
when adherence is optimized, especially when combined 
with “treatment as prevention” for the partner living with 
HIV.14–17 Mathematical modeling suggests optimal PrEP 
coverage in a largely heterosexual epidemic could reduce 
new infections by up to 39% over 10 years.18 In the 
Bangkok Tenofovir Trial, the only randomized clinical 
trial of PrEP for people who inject drugs (PWID), teno-
fovir was associated with a 79% reduction in HIV acqui-
sition compared to placebo among the 489 women 
enrolled.19,20
In real-world settings, women’s PrEP use is consis-
tently limited by: 1) lack of awareness that PrEP is an 
effective prevention strategy;21 and 2) misestimation of 
personal HIV risk, especially among women with 
SUDs.22–28 Since TDF/FTC (Truvada®) was FDA- 
approved for PrEP in 2012, fewer than 5% of US women 
meeting clinical criteria have received it, and they are 
disproportionately non-Hispanic White, which does not 
demographically reflect the HIV epidemic among 
women.29–31
The current study aims to address deficits in PrEP 
scale-up22 for women with SUDs by empowering them 
to make informed choices about effective HIV prevention 
options, including PrEP. In response to a call for patient- 
led decision-making interventions on PrEP,32 we devel-
oped and tested an informed, patient-centered decision 
aid (DA) on PrEP for women in addiction treatment. In 
contrast to generalized information-education-counselling 
approaches, patient-centered DAs convey specific and 
value-congruent personal health options, thereby encoura-
ging active consumer participation.33 To our knowledge, to 
date, there have been no published DAs for PrEP for HIV 
prevention and none tailored to women with SUD.32,34,35
Methods
Study Setting
The study, known as OPTIONS (registered as 
NCT03651453 on Clinicaltrials.gov), was conducted at 
Connecticut’s largest addiction treatment center, which 
provides comprehensive services including primary care, 
both ambulatory and residential treatment, and medica-
tions for opioid use disorder (MOUD). Across four sites 
with an open access policy,36 there are approximately 300 
new intakes per month, one-third of whom are women. 
HIV testing is offered at intake and PrEP is available for 
patients who request it through onsite primary care.
We integrated data from individual semi-structured 
qualitative interviews, focus groups, workshops and topi-
cal experts to develop a DA for PrEP tailored to women 
enrolled in addiction treatment. The development pro-
cesses occurred between December 2017 and 
September 2018 and qualitative findings are described 
elsewhere.37 The final DA was reviewed for adherence to 
International Patient Decision Aids Standards (IPDAS).38 
The elements of the DA involved a discussion on the pros 
and cons of using PrEP relative to other prevention stra-
tegies, addressing domains identified as important to 
women with SUDs, including PrEP’s efficacy, cost, side 
effects, medication interactions, insurance coverage, and 
need for disclosure to partners.
https://doi.org/10.2147/PPA.S315543                                                                                                                                                                                                                                  
DovePress                                                                                                                                               
Patient Preference and Adherence 2021:15 1914
Meyer et al                                                                                                                                                           Dovepress



































































Recruitment and Study Sample
Participants were recruited to the study from the treatment 
program by trained research assistants. Treatment program 
staff also provided a list of clients who expressed general 
interest in participating in clinical research; the research team 
contacted these individuals directly to describe the study and 
screen for eligibility. Addiction treatment staff could directly 
refer clients. Promotional material was also available through-
out the facilities, allowing clients to self-refer to the study 
using a HIPAA-secure Qualtrics link or a dedicated study 
phone line.
Members of the research team screened all interested 
women in a private space for the following eligibility 
criteria: self-identification as female (ie, cis- or trans- 
women), age ≥18, self-reported HIV-uninfected or status 
unknown, and entering or receiving addiction treatment. 
Individuals were excluded if they were unable or unwilling 
to provide written informed consent, experiencing physio-
logic symptoms of withdrawal that could interfere with 
their ability to provide informed consent, participated in 
formative phases of the project (to minimize selection 
bias), or were already on PrEP or enrolled in other PrEP- 
related research studies. All participants provided written 
informed consent and signed a release of information form 
to access the electronic health record (EHR) and other 
quality improvement data at the addiction treatment clinic. 
All procedures were approved by the institutional review 
board at Yale University and the Board of Directors at the 
treatment program. The study was conducted in accor-
dance with the Declaration of Helsinki.
Intervention Delivery
Enrollment occurred between October 2018 and 
October 2019. After consent procedures, study interviews 
were conducted in English or Spanish by a trained 
researcher using RedCAP. During the baseline interview, 
participants were provided with a brief description of PrEP 
as an “HIV prevention pill” and asked, do you want to 
learn more about PrEP? Those who answered affirmatively 
were preferentially assigned to engage with the DA. Those 
selecting not to receive more information were assigned to 
receive an enhanced standard of care (eSOC). The ratio-
nale for using a natural preference design, rather than 
randomization, was to more precisely reflect individua-
lized decision-making processes in “real world” settings, 
where individuals often need different types of support and 
information to make decisions. We were interested in 
understanding who, when, and how individuals needed 
support to make choices about PrEP. Participants who 
opted into the “more information” DA arm engaged with 
the DA through a client-facing screen on RedCAP in the 
presence of a trained research assistant. Enhanced standard 
of care (eSOC) involved providing a phone number and 
website for more information about HIV prevention and 
where PrEP could be accessed, without any additional 
personalized assessment or coaching. This is more than 
the information about PrEP that is typically provided in 
addiction treatment settings. There was no intervention to 
actively link participants to PrEP clinical services or 
directly provide PrEP to participants in either arm.
Study Assessments and Data Extraction
All study interviews were conducted using RedCAP in 
a private room and used standardized instruments in 
English or Spanish at baseline and quarterly for 12 months. 
Participants were paid $20 for the baseline and $5 for the 
brief, quarterly follow-up interviews, done in person or by 
phone or text depending on participant preference.
The EHR in the treatment program was manually 
reviewed using a standardized chart abstraction tool for 
active current substance use and psychiatric disorder diag-
noses using ICD-10 codes, and testing dates and results for 
HIV and Hepatitis C (HCV). A linked treatment center 
database was then electronically queried for quality 
improvement measures, which are collected at treatment 
center admission for all patients for program planning 
purposes and to characterize the population (as is being 
done here). Quality improvement measures included the 
life events checklist (LEC-5),39 Behavior and Symptom 
Identification Scale, Adult version (BASIS-24),40 and 
Generalized Self-Efficacy scale.41 All extracted data were 
merged into the RedCAP database.
Measures
The primary outcome, and the first decision point in the HIV 
prevention cascade, was opting for “more information” via 
the DA, the measurement of and rationale for which is 
described above. We also assessed the efficacy of the DA 
in terms of modifying the decisional preference for PrEP at 
baseline for both groups using the 5-point Likert scale ques-
tion: Would you take PrEP if it were available to you? 
Responses were analyzed continuously and categorized into 
3 groups: 1) No; 2) Unsure, I do not know what PrEP is, or 
Maybe but I need more information; and 3) Yes and I am 
ready to start immediately or Yes but not right now. 
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Immediately after completing the DA, DA-selecting partici-
pants were asked, Now that you have learned more about 
PrEP, how likely are you to use it? Responses were given on 
a 5-point Likert scale and assessed as an ordinal variable and 
dichotomized as likely versus unlikely. Participants were 
then asked to select which information presented in the DA 
contributed most to their decision about PrEP. Perception of 
HIV risk was determined at baseline and quarterly thereafter 
by the question, How likely are you to become infected with 
HIV? and assessed on a 5-point Likert scale from Not at all 
likely to Extremely likely. Scores were analyzed both cate-
gorically and continuously.
An exploratory efficacy outcome, PrEP uptake, was 
assessed at 3-, 6-, 9- and 12-month post-enrollment and 
operationalized as self-reporting a clinical visit with 
a provider for the purposes of starting PrEP. Pharmacy or 
clinic data were not available for verification; all PrEP 
engagement was self-reported.
Demographic and social characteristic variables 
included marital status, which was categorized as currently 
married or not married (ie widowed, separated, divorced, 
or never married.) Housing status was categorized as 
“usual” living arrangements over the past 3 years and 
past 30-days (in a house or apartment, unstable or transi-
tional, controlled setting). Healthcare engagement was 
measured as time since “last checkup by a primary care 
provider” and dichotomized at one year.
Substance use severity was assessed using the drug sub-
scale on the Addiction Severity Index (ASI-D); scores were 
assessed continuously and dichotomized at pre-specified 
validated cutoffs for severe alcohol (≥0.17) and drug 
(≥0.12) use.42,45 Alcohol use severity was also evaluated at 
baseline using the World Health Organization’s Alcohol Use 
Disorders Identification Test (AUDIT),43 with harmful or 
hazardous drinking for women defined as scores ≥4.44 
Substance use disorder diagnoses from the EHR included 
alcohol, opioid, and cocaine use disorders.
Psychiatric disorders were evaluated at baseline using 
the psychiatric subscale of the ASI (ie, ASI-P) as 
a continuous score with severe lifetime psychiatric disorders 
dichotomized at 0.22.45 The following psychiatric disorder 
diagnoses were extracted from the EHR: bipolar disorder, 
anxiety disorder, post-traumatic stress disorder (PTSD), and 
major depressive disorder. Lifetime trauma was assessed by 
the LEC-5,39 including personally experiencing: 1) physical 
assault (being attacked, hit, slapped, kicked, beaten up); 2) 
assault with a weapon (being shot, stabbed, threatened with 
a knife, gun, bomb); or 3) sexual assault (rape, attempted 
rape, made to perform any type of sexual act through force 
or threat of harm). Behavioral health was assessed by the 
BASIS-2440 to evaluate functioning within the past week 
along various domains; each item is scored on a Likert scale 
from 0 to 4, with higher scores indicating more extreme 
difficulty. Self-efficacy was measured by the 10-item 
Generalized Self-Efficacy Scale,41 with each item on 
a Likert scale from 1 (not at all true) to 4 (exactly true), 
with sum scores ranging from 10 to 40.
HIV risk was evaluated using standard measures of sex 
and drug risk from NIDA’s modified risk behavior 
assessment46 and adjusted to include CDC-based clinical 
eligibility criteria for PrEP.47 Participants were asked at 
baseline about whether they had engaged in any of the 
following behaviors within the prior 6 months: 1) condom-
less sex with a high-risk partner (ie, a man with HIV who 
was not on treatment, a man with unknown HIV status, 
a man who injected drugs, or while intoxicated); 2) injec-
tion drug use and sharing any injecting equipment; 3) 
transactional sex (defined as the exchange of sex for 
drugs, money, goods, or other services); or 4) diagnosed 
with a bacterial sexually transmitted infection. We 
assessed the total number of different HIV risk behaviors 
reported for each individual. At each follow-up visit, par-
ticipants were asked about interim 3-month HIV risk beha-
viors. PrEP eligibility was determined by current clinical 
guidelines.48 We calculated risk underestimation as being 
eligible for PrEP (and therefore having a high HIV risk) 
but perceiving a low HIV risk. We evaluated whether 
participants had ever had HIV and HCV testing recorded 
in the EHR, and associated results.
Statistical Analysis
Descriptive statistics were used to characterize the study 
sample, comparing those who opted into the DA to those 
who received eSOC, using Chi-squared or Fisher’s exact 
tests for categorical variables and independent Student’s 
t-test for continuous variables. The purpose of the compara-
tive analysis was to assess for differences in participants who 
opted in or out of requesting more information from the DA, 
which is important for understanding this first decision step as 
an outcome. We used logistic regression to model the primary 
outcome of interest with more information, ie, opting for the 
DA. After assessing bivariate associations between demo-
graphic or clinical factors and the primary outcome, 
a parsimonious logistic regression model was developed that 
included bivariate associations significant at p<0.2 Based on 
goodness-of-fit testing, the BASIS-24 relationship domain 
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was excluded from the multivariate model for collinearity 
with social support. We used paired t-tests to compare mean 
PrEP interest before and after the DA for those selecting the 
DA. We used descriptive statistics to assess longitudinal PrEP 
outcomes by the study arm. Statistical significance was 
defined as p<0.05 All analyses were conducted using SAS 
version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Among the 216 women with SUD assessed for study eligibil-
ity, 164 (75.9%) were enrolled after excluding 12 for not 
meeting study criteria and 40 for inability to contact them or 
other logistical reasons (Figure 1). Among those enrolled 
(N=164), 83 selected more information using the DA and 81 
chose eSOC. After 3 months, study retention was similar in the 
DA and eSOC arms (82% versus 73%; p=0.16). Moreover, 
there were no significant differences in demographic or 
clinical characteristics of participants missing versus not miss-
ing at any time point over the 12 months of follow-up.
The sample (Table 1) was demographically representa-
tive of women in addiction treatment locally and 
nationally.49 Women were, on average, 40.4 years old, 
with the majority being non-Hispanic and white. Many 
had a high-school education, were unemployed, housed, 
and had seen a healthcare provider within the past year 
(79.9%). Most participants (92.1%) had opioid use disor-
der and over half met criteria for severe substance use. 
Fewer women were diagnosed with alcohol use disorder 
recorded in the EHR (14.0%) relative to those who 
screened positive for hazardous drinking using the 
AUDIT (31.7%). Psychiatric disorders were also highly 
prevalent in the sample, with approximately one-third 
having been diagnosed with anxiety, post-traumatic stress, 
and/or major depressive disorders. An even higher propor-
tion of participants experienced lifetime trauma that 
Figure 1 CONSORT Flow Diagram of Participant Allocation.
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included physical and sexual assaults. Daily functioning 
was negatively impacted by depression, emotional lability, 
and substance use, as reflected in high BASIS-24 scores in 
each of these domains. Criminal justice involvement was 
also relatively high in the cohort overall. Women experi-
enced a mean 3.8 (SD 8.8) of lifetime arrests and mean 9.6 
months (SD 29.3) of lifetime incarceration; there were no 
significant differences between the two arms in terms of 
these factors.
DA participants had significantly higher lifetime alco-
hol use severity relative to the eSOC group (13.3% 
v. 3.7%, p=0.03; Table 1). Although not statistically sig-
nificant, we also observed differences in relationship mea-
sures between the two arms in that participants in the DA 
arm had relatively higher (ie, more disruptive) relationship 
scores on the BASIS-24 and lower overall social support 
scores. Otherwise, there were no observed differences 
between the DA and eSOC groups in terms of demo-
graphic or clinical factors.
Though not shown in Tables 1, 70 participants (42.7%) 
had completed recent HIV testing (all were HIV negative). 
Overall, 76 (46.3%) had completed HCV testing, of whom 
30 screened positive for HCV antibody, and 6 had detect-
able HCV RNA, indicating untreated chronic HCV infec-
tion. Completion of HIV or HCV testing did not differ by 
study arm, though among participants with a positive HCV 
antibody, DA participants more often had undetectable 
HCV RNA levels, suggesting treated or spontaneously 
cleared infection.
Table 2 presents HIV risk and PrEP interest by study 
arm. Baseline risk behaviors were common at baseline, 
including recent condomless sex (73.9%), injection drug 
use (32.1%), transactional sex (9.7%), and recently diag-
nosed sexually transmitted infections (6.1%), resulting in 
over half (52%) of the overall sample meeting PrEP elig-
ibility criteria. There were no significant differences 
between the two arms in terms of HIV risk behaviors or 
PrEP eligibility, though DA participants were significantly 
more likely to have a higher perceived risk for acquiring 
HIV (25.6% vs 10.4%; p=0.01). Baseline interest in PrEP 
was marginally higher in the DA arm (25.3% vs 24.7%), 
as was the ambivalence about taking PrEP (73.5% 
vs 65.4%).
Table 3 depicts bivariate and independent correlates of 
selecting to receive more information using the DA. After 
controlling for other factors, the only two statistically 
significant correlates of selecting more information using 
the DA were alcohol use severity (aOR 4.13, 95% CI 
1.05–16.28, p=0.04) and high perceived risk for acquiring 
HIV (aOR 2.95, 95% CI 1.19–7.35, p=0.02). Notably, 
PrEP eligibility and HIV risk underestimation were not 
associated with interest in receiving more information 
using the DA in the multivariate model.
We then turned to evaluating the effect of the DA on 
decisional preference for PrEP. Among the 83 women in 
the DA arm, interest in PrEP significantly increased from 
25.3% to 89.2% after receiving the DA (Figure 2). This 
finding aligned with PrEP interest using the 5-point Likert 
Figure 2 Longitudinal PrEP Outcomes by Study Arm (N=164). 
Abbreviation: eSOC, enhanced standard of care.
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Table 1 Baseline Characteristics of the Study Sample by Arm (N=164)
Characteristic Total Sample N=164 Decision Aid N=83 eSOC N=81 p-value
Mean age, SD 40.4 (10.3) 40.4 (10.4) 40.4 (10.3) 0.96
Race 0.69
White 123 (75.0) 62 (74.7) 61 (75.3)
Black 26 (15.9) 12 (14.5) 14 (17.3)
Other 15 (9.2) 9 (10.8) 6 (7.4)
Ethnicity 0.84
Hispanic 17 (10.4) 9 (10.8) 8 (9.9)
Non-Hispanic 147 (89.6) 74 (89.2) 73 (9.1)
Education completed 0.55
Less than high school 31 (18.9) 18 (21.7) 13 (16.1)
High school 73 (44.5) 34 (41.0) 39 (48.2)
More than high school 60 (36.6) 31 (37.4) 29 (35.8)
Median monthly income, IQR 793 (798) 871 (842) 700 (753) 0.48
Employment Status 0.21
Full time 74 (15.1) 32 (38.6) 42 (51.9)
Part time 37 (22.6) 20 (24.1) 17 (21.0)
Retired/Disability 17 (10.4) 12 (14.5) 5 (6.2)
Unemployed 36 (22.0) 19 (22.9) 17 (21.0)
Marital status N=163 N=83 N=80 0.21
Married 36 (22.1) 15 (18.1) 21 (26.3)
Not/never married 127 (77.9) 68 (81.9) 59 (73.8)
Past 3-year living arrangement 0.63
Alone 18 (11.0) 11 (13.3) 7 (8.6)
Controlled/Unstable 14 (8.5) 6 (7.2) 8 (9.9)
With family/friends/parents 38 (23.2) 17 (20.5) 21 (25.9)
With children/partner 94 (57.3) 49 (59.0) 45 (55.6)
Past 30d housing status N=118 N=61 N=57 0.37a
House/apartment 87 (73.7) 78 (78.7) 39 (68.4)
Unstable/Transitional 24 (20.3) 10 (16.4) 14 (25.5)
Controlled setting 7 (5.9) 3 (4.9) 4 (7.0)
Last healthcare provider visit 0.91
Within past year 131 (79.9) 66 (79.5) 65 (80.3)
More than 1 year prior 33 (20.1) 17 (20.5) 16 (19.8)
Mean Addiction Severity score, SD
Alcohol 0.04 (0.13) 0.07 (0.17) 0.02 (0.06) 0.02
Drugs 0.16 (0.17) 0.17 (0.17) 0.16 (0.16) 0.62
Severe lifetime alcohol use 14 (8.5) 11 (13.3) 3 (3.7) 0.03a
Severe lifetime drug use 88 (53.7) 46 (55.4) 42 (51.9) 0.65
Hazardous drinking 52 (31.7) 26 (31.3) 26 (32.1) 0.92
Mean Psychiatric Severity score, SD 0.33 (0.25) 0.35 (0.25) 0.32 (0.24) 0.44
Severe lifetime psychiatric issue 111 (67.7) 57 (68.7) 54 (66.7) 0.78
(Continued)
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scale, significantly increasing from before (mean 2.95 [SD 
1.2]) to after (mean 3.40 [SD 1.2]; p=0.003) receiving the 
DA. The most common factor driving participants’ PrEP 
interest was an understanding from the DA about the PrEP 
efficacy of preventing HIV, followed by information about 
side effects, and personal risk.
Use of the PrEP DA significantly transitioned partici-
pants along the PrEP care continuum50 from interest to 
action. Over 12 months of follow-up, 18 (10.9%) women 
saw a healthcare provider for PrEP, which was significantly 
higher among women selecting the DA than those who did 
not (15.7% vs 6.2%; p=0.04), despite similar levels of HIV 
risk. Women selecting to use the DA, however, took longer 
to see a PrEP provider than eSOC participants (mean 32.5 
[SD 88.4] vs 11.0 [SD 45.6] days; p=0.05). There were no 
significant changes in reported risk behaviors over time for 
retained participants in either arm. At month 12, partici-
pants in the DA arm were somewhat less likely than those in 
Table 1 (Continued). 
Characteristic Total Sample N=164 Decision Aid N=83 eSOC N=81 p-value
Type of substance use disorder
Alcohol use disorder 23 (14.0) 14 (16.9) 9 (11.1) 0.29
Opioid use disorder 151 (92.1) 76 (91.6) 75 (92.6) 0.81
Cocaine use disorder 69 (42.1) 32 (38.6) 37 (45.7) 0.36
Psychiatric disorders
Bipolar disorder 31 (18.9) 16 (19.3) 15 (18.5) 0.90
Anxiety disorder 63 (38.4) 36 (43.4) 27 (33.3) 0.19
PTSD 47 (28.7) 27 (32.5) 20 (24.7) 0.27
Major depressive disorder 47 (28.7) 29 (34.9) 18 (22.2) 0.07
Experienced trauma N=102 N=51 N=51
Physical assault 68 (66.7) 35 (68.6) 33 (64.7) 0.67
Assault with weapon 29 (28.4) 14 (27.5) 15 (29.4) 0.83
Sexual assault 53 (52.0) 25 (49.0) 28 (54.9) 0.55
Mean BASIS-24 score (SD) N=122 N=63 N=59
Overall score 1.67 (0.75) 1.69 (0.74) 1.65 (0.77) 0.77
Depression/functioning 2.08 (1.03) 2.11 (1.03) 2.05 (1.53) 0.74
Relationships 1.56 (0.90) 1.68 (0.95) 1.43 (0.84) 0.13
Self-Harm 0.35 (0.64) 0.32 (0.55) 0.38 (0.72) 0.62
Emotional Lability 1.90 (1.00) 1.94 (0.97) 1.86 (1.00) 0.67
Psychosis 0.53 (0.89) 0.49 (0.85) 0.57 (0.93) 0.60
Substance Abuse 2.25 (1.13) 2.15 (1.13) 2.36 (1.12) 0.31
Mean Self-efficacy (SD) N=86 N=44 N=42
29.1 (5.8) 29.1 (6.0) 29.1 (5.7) 0.97
Mean Social Support score, SD 73.5 (23.7) 70.8 (25.1) 76.3 (22.0) 0.14
Main source of social support n=162 n=82 n=80
Partner 49 (30.3) 23 (28.1) 26 (32.5) 0.54
Family 67 (41.4) 34 (41.5) 33 (41.3) 0.98
Community/church 11 (6.8) 7 (8.5) 4 (5.0) 0.53a
Other 9 (5.6) 5 (6.1) 4 (5.0) 1.0
No one 9 (5.6) 6 (7.3) 3 (3.8) 0.50
Mean no. lifetime arrests (SD) N=163 N=83 N=80 0.09
3.8 (8.8) 4.9 (11.7) 2.7 (4.3)
Mean months lifetime incarceration (SD) 9.6 (29.3) 9.5 (25.9) 9.7 (32.6) 0.95
Note: aFisher's exact test. 
Abbreviations: eSOC, enhanced standard of care; SD, standard deviation; IQR, interquartile range; PTSD, post-traumatic stress disorder; ASI, addiction severity index for 
psychiatric disorders (-P) and depression (-D).
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eSOC to underestimate their HIV risk (25.0% vs 32.1%; 
p=0.43).
Discussion
To our knowledge, this is the first reported PrEP DA 
developed for and tested in women with SUDs in addic-
tion treatment programs. Preliminary findings here suggest 
that such an aid can have transformative value in accel-
erating the PrEP care continuum for high-risk women and 
contribute to the EHE strategy. Important in these findings 
is that women who (accurately) perceived themselves to be 
at high-risk for HIV and those with higher alcohol use 
severity were more likely to opt for a PrEP DA. Though 
actual and perceived risks were similar between the two 
groups, those selecting to engage with the DA were more 
ambivalent about PrEP and engagement with the aid not 
only substantially increased interest but also resulted in 
significantly more women starting PrEP.
Health-related decisions emerge from a combination of 
a person’s knowledge and perceptions. Although accurate 
knowledge may play a large role in patient decision- 
making, its role is variable for some patients and for 
some decisions.51 In terms of the decision to take PrEP, 
the DA involved a combination of knowledge elements 
(eg, efficacy at preventing HIV, side effects) and there was 
a three-fold increase in PrEP interest after using the DA. 
By building women’s knowledge about PrEP, the DA 
generated interest in PrEP.
Women’s decision to receive more information about 
PrEP through the DA was heavily based on their perceived 
HIV risk, wherein women in the DA arm more often 
perceived that they were at-risk for HIV (25.6% vs 
10.4%) and thus could potentially benefit from PrEP. 
Underestimation of personal risk is common among 
women at highest risk for HIV. In a survey we did of 
125 women on probation or parole, most of whom had 
SUDs, we found 33% were clinically eligible for PrEP, but 
only 17% perceived they were at risk for HIV.52 We also 
found high rates of risk underestimation among women in 
prison.53 This echoes larger surveys of US women, 
wherein limited awareness of PrEP and underestimation 
Table 2 HIV Risk and PrEP Interest by Study Arm (N=164)
Characteristic Total Sample N=164 Decision Aid N=83 eSOC N=81 p-value
Mean categories HIV risk behaviors (SD) 2.3 (2.0) 2.5 (2.1) 2.0 (1.8) 0.16
Baseline HIV risk perception for acquiring HIV N=155 N=78 N=77 0.01
Somewhat/extremely likely 28 (18.1) 20 (25.6) 8 (10.4)
Unlikely/not at all 127 (81.9) 58 (74.4) 69 (89.6)
Baseline PrEP eligible 85 (51.8) 47 (56.6) 38 (46.9) 0.21
Underestimate risk 58 (37.4) 28 (35.9) 30 (39.0) 0.69
PrEP interest – pre-selection 0.05
No 9 (5.5) 1 (1.2) 8 (9.9)
Yes 41 (25.0) 21 (25.3) 20 (24.7)
Ambivalent 114 (69.5) 61 (73.5) 53 (65.4)
PrEP interest – post-decision aid n/a n/a n/a
Likely/very likely 74 (89.2)
Unlikely/not at all 9 (10.8)
Most important factor influenced by decision aid n/a n/a
Personal risk 11 (6.7)
Effective at preventing HIV 44 (26.7)
How it works 5 (3.0)
Insurance coverage 1 (0.6)
Side effects 11 (6.7)
What is involved 2 (1.2)
Medication interactions 6 (3.6)
Other 3 (1.8)
Abbreviation: eSOC, enhanced standard of care.
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of HIV risk has generated severe under-utilization of PrEP 
in women.21,54,55 Misestimation may result from cognitive 
biases, including denial and unconscious minimization of 
risky behaviors in the setting of pervasive loss of auton-
omy, particularly among women with SUDs.
Reports from DA participants point to yet another 
dimension of DAs– reorienting personal HIV risk 
estimation to jumpstart PrEP initiation. Women’s realistic 
self-estimation of HIV risk can be especially challenging 
because current clinical guidelines for PrEP require 
women to assess their partner’s behaviors (eg, injection 
drug use, sex with men, etc.), which may be impractical 
because women’s access to this information depends on 
their partners’ disclosures. One alternative strategy is to 
Table 3 Bivariate and Independent Correlates for Selecting for More Information Using a Decision Aid
Variables Bivariate Analysis Multivariate Analysis
Decision Aid OR (95% CI) p-value Decision Aid aOR (95% CI) p-value
Age 0.99 (0.97, 1.03) 0.96
Race 0.69
White REF
Black 0.84 (0.36, 1.97)
Other 1.48 (0.50, 4.40)
Hispanic 1.11 (0.41, 3.03) 0.84
Marital status 0.21
Married REF
Not/never married 0.62 (0.29, 1.31)
Past 3-year living arrangement 0.63
Alone REF
Controlled/Unstable 0.48 (0.12, 1.98)
With family/friends 0.52 (0.16, 1.62)
With children/partner 0.69 (0.25, 1.94)
Education completed 0.55
Less than high school REF
High school 0.63 (0.27, 1.47)
More than high school 0.77 (0.32, 1.85)
Last healthcare provider visit within past year 0.96 (0.45, 2.05) 0.91
Alcohol use disorder 1.62 (0.66, 3.99) 0.29
Lifetime severe alcohol use 3.97 (1.07, 14.81) 0.04 4.13 (1.05, 16.28) 0.04
Cocaine use disorder 0.75 (0.40, 1.39) 0.36
Anxiety 1.53 (0.81, 2.89) 0.19 1.87 (0.94, 3.70) 0.07
PTSD 1.47 (0.74, 2.91) 0.27
BASIS-24 – relationships domain 1.37 (0.94, 2.05) 0.13
Social support 0.99 (0.98, 1.00) 0.14 0.99 (0.98, 1.01) 0.32
Underestimate HIV risk 0.88 (0.46, 1.68) 0.69
PrEP eligible 1.48 (0.80, 2.73) 0.21
High perceived HIV risk 2.97 (1.22, 7.25) 0.02 2.95 (1.19, 7.35) 0.02
PrEP ambivalence 1.47 (0.75, 2.86) 0.26
Abbreviations: OR, odds ratio; aOR, adjusted odds ratio; PTSD, post-traumatic stress disorder.
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assess external factors, such as personal and partners’ 
criminal justice involvement or intimate partner violence 
exposure, that have been shown to be associated with 
incident HIV in women.56–58 Still, women may be reluc-
tant to disclose these factors to healthcare providers 
because of anticipated stigma. Clinicians often underesti-
mate (or do not even consider) women’s eligibility for 
PrEP, even in the most optimistic scenarios when clini-
cians appropriately enquire about risk and women feel 
comfortable enough to respond honestly.59,60 Therefore, 
moving the dialogue about PrEP decision-making to 
a purely objective interface where both risk is assessed 
and alternatives are presented may help overcome the 
PrEP delivery gap for women. Such innovations could be 
enhanced by directing women’s DA output to her health-
care provider to extend the dialogue further as part of 
a shared decision-making process.
The finding that alcohol use severity was associated 
with women selecting to use the DA is intriguing. Alcohol 
use is an independent risk factor for HIV, related to intox-
ication-associated disinhibition, condomless sex, and 
increased risk-taking.61 For PWH, severe alcohol use dis-
order is associated with delayed HIV diagnosis and 
reduced treatment engagement and viral suppression,62,63 
suggesting alcohol use may effect health-related decision- 
making. Conversely, evidence-based treatment of alcohol 
use disorders with medications (eg naltrexone) is asso-
ciated with decreased alcohol consumption64 and 
improved HIV treatment outcomes.65 While treatment for 
SUDs has been shown to reduce women’s injection-related 
HIV risk, it has not successfully reduced women’s sex- 
related HIV risk.66 We did not find here that alcohol use 
severity was associated with HIV risk behaviors. An alter-
native explanation for how alcohol use severity impacted 
medical decision-making, and thus interest in receiving 
more information through the DA, is via alcohol-related 
neurocognitive impairment (NCI), which is highly preva-
lent among people with SUDs.67,68 We did not directly 
measure NCI here, but prior studies of people with SUDs 
at similarly high-risk for HIV have found that NCI was 
associated with increased interest in an mHealth tool to 
support PrEP adherence and reinforce risk reduction skills, 
which has some overlaps with the DA.69
Though exploratory in nature due to the sample size, 
other factors may be important in a woman’s decision to 
select a PrEP DA. For example, in the bivariate analysis, 
DA participants had higher levels of relationship dysfunc-
tion and lower levels of social support, relative to eSOC 
participants. This finding may suggest that women who are 
less supported (and thus less exposed to positive peer 
influence) may seek more intensive information from 
new sources (like a DA) to make individual decisions 
about their health. Alternatively, women who experience 
lower support from family or peers may perceive informa-
tion from these sources as unreliable and thereby women 
seek out information from a potentially reputable source 
like the DA. Relationship factors are especially important 
for women’s medical decision-making and HIV risk 
because women often experience HIV risk through inti-
mate partners and have overlapping sex and drug use 
partners that synergistically increases potential exposure 
to HIV.70
Relationship factors influencing DA uptake were also 
reflected in interpersonal violence exposure. Enrolled par-
ticipants had extremely high rates of diagnosed PTSD and 
lifetime trauma that included physical assault, assault with 
a weapon, and sexual assault. In other samples of men and 
women with SUD in treatment, 80–92% report lifetime 
traumatic experiences and 30–60% have diagnosed 
PTSD.71,72 Violence exposure broadly impacts women’s 
health-related decision-making, HIV risk, risk perception, 
and relationship stability.73–75 Although we did not expli-
citly design the DA to be trauma-responsive, we did 
design it to be women-centered and empowerment 
oriented, and we used trauma-responsive delivery 
approaches, including delivering the DA in a closed pri-
vate setting after building rapport with a single female 
member of the research team. If the DA is to be more 
widely disseminated and implemented in treatment set-
tings, it will be important to ensure it is done in a way 
that is trauma-responsive to meaningfully engage women 
at highest risk of HIV. We did not find that diagnosed 
trauma was associated with choosing more information 
through the DA, though intimate partner violence exposure 
could have contributed to many of our findings. 
A principal component or latent class analysis might 
have better elucidated this factor since intimate partner 
violence exposure was not explicitly measured here.
This study is not without limitations. It was conducted 
at a single site in the Northeast US and cannot be fully 
generalized to all other contexts where resources and PrEP 
services may differ. Moreover, the sample was limited to 
women enrolled in addiction treatment, and decision- 
making may differ for women not in treatment who must 
navigate a myriad of other stressors, including their sub-
stance use. Race is an important sociocultural 
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consideration in terms of who can access addiction treat-
ment, since non-Hispanic and white women are overrepre-
sented in SUD treatment nationally, as reflected in our 
sample. Further adaptations may be needed to make the 
DA more culturally congruent for women who identify as 
Black and Hispanic. Study arm was allocated by partici-
pant preference rather than randomization, which poses 
two potential biases: 1) unbalanced allocation, which did 
not occur; and 2) allocation bias, which we did not find to 
be the case in terms of key demographic and clinical 
characteristics. There may be unmeasured variables con-
tributing to study arm allocation, though we evaluated the 
study arm allocation decision as an outcome unto itself as 
the first step in the decision-making process of PrEP. Some 
outcomes were self-reported and may have been influ-
enced by social desirability bias. Missingness at random 
was not formally assessed.
Though we did find that DA participants were signifi-
cantly more likely to start PrEP, future studies should 
incorporate a Test and Prevent model where women with-
out HIV are assessed with a DA and linked directly to 
PrEP services, potentially with patient navigators or other 
linkage strategies. Although HIV prevention can be incor-
porated into a broad range of primary care settings,76 it is 
particularly poignant in addiction treatment settings 
because nearly 1.5 million women access treatment for 
alcohol or illicit drugs annually77 and drug treatment is 
effective HIV prevention.78 A meta-analysis found consis-
tently positive effects of integrated HIV prevention pro-
grams into drug treatment settings for knowledge, skills, 
and behaviors,79 supported by recently pooled results 
across the Clinical Trials Network,80 and specifically for 
women.66 Future studies should focus on DA implementa-
tion, including integration into the EHR in addiction treat-
ment settings and expanding the DA to include shared 
decision-making with onsite clinicians.20,81 Clinicians in 
these settings are often not PrEP prescribers but have far 
more frequent patient contact than prescribers do, includ-
ing at key touchpoints like treatment entry and repeated 
treatment planning, which are ideal opportunities for DA 
delivery.
Conclusions
The findings support the beneficial effect of a novel PrEP 
DA on preference for PrEP among women with SUD in 
treatment, including those experiencing the highest HIV 
risk. Ideally, the DA tool would be in front of eligible 
women before they meet clinicians, as this may be a key 
implementation step. Future research should test this 
hypothesis.
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